Mysthera Therapeutics AG has launched in Basel with $3.5m in seed funding from founding investor Forty51 Ventures. The capital will be used to advance its preclinical portfolio in a variety of autoimmune indications. The focus is on pan-PIM kinase inhibitors that uniquely modulate multilineage immune cell functions.
Women’s health specialist Mithra Pharmaceuticals SA has entered into a definitive agreement to raise 20m in gross proceeds via a private placement of 10 million new ordinary shares with Armistice Capital.
ETH Zurich researchers have developed a gene switch that triggers insulin release in designer cells by playing music.
Oil-eating bacteria form dendritic biofilms that reshape oil droplets to speed up the rate of consumption
French vaccine maker Valneva SE will double the amount of a US$100m debt financing granted by Deerfield Management Company and OrbiMed.
Swiss Spexis AG has announced a US$2.5m capital commitment to fund a two-part pivotal Phase III study to get market approval for its inhaled cystic fibrosis antibiotic colistimethate sodium.
With a US$1bn acquisition of Canadian Inversago Pharma, Novo Nordisk A/S fiights to maintain its dominant position in the booming weight loss drug market.
British researchers have proven that a new gene can prevent progression of hereditary kidney damage in mice.
Lipid, nutrition and frozen bakery specialist Allianza Team puts £900,500 into pre-Series A financing of microbial palm oil producer Clean Food Group Ltd.
A Dutch-German team of researchers has found out that the amount of not degradable plastics is lower than estimated but that they persist for longer than previously assumed.